+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alpha Antitrypsin Deficiency - Epidemiology Forecast to 2030

  • ID: 4330786
  • Report
  • April 2020
  • Region: Global
  • 100 pages
  • DelveInsight
‘Alpha Antitrypsin Deficiency - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Alpha Antitrypsin Deficiency in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2030

Alpha Antitrypsin Deficiency Disease Understanding

Alpha Antitrypsin Deficiency (AATD) occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. AAT protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.

Alpha Antitrypsin Deficiency Epidemiology

The Alpha Antitrypsin Deficiency epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. The epidemiology data for Alpha Antitrypsin Deficiency are studied through all possible division to give a better understanding about the Disease scenario in 6MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Alpha Antitrypsin Deficiency Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017-2030.

The report also provides the epidemiology trends observed in the 6MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to the publisher, the total number of prevalent cases of Alpha Antitrypsin Deficiency in 6MM was found to be 175,009, in the year 2017.

Report Scope
  • The report covers detailed overview of Alpha Antitrypsin Deficiency explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Alpha Antitrypsin Deficiency in 6 major markets covering the United States and EU5 (Germany, Spain, France, Italy, UK).
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 6MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD in 6MM
Key strengths
  • 11 Year Forecast of Alpha Antitrypsin Deficiency epidemiology
  • 6MM Coverage
  • Total Prevalent Cases of AATDs
  • Prevalent Cases according to segmentation: (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD)
Key Assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
1 Key Insights

2 Executive Summary of Alpha Antitrypsin Deficiency

3 SWOT Analysis for Alpha Antitrypsin Deficiency

4 Patient Share of Alpha Antitrypsin Deficiency at a Glance
4.1 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2017
4.2 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2030

5 Alpha Antitrypsin Deficiency Market Overview at a Glance
5.1 Diagnosed Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2017
5.2 Diagnosed Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2030

6 Disease Background and Overview
6.1 Introduction
6.2 Symptoms
6.3 Etiology
6.4 Risk Factors
6.5 Genetic Inheritance of AAT Deficiency
6.6 Clinical Manifestations
6.7 Pathophysiology
6.8 Biomarkers
6.9 Diagnosis
6.1 Diagnostic Delay

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM

8 Country-wise Epidemiology of Alpha-1-Antitrypsin Deficiency
8.1 Assumptions and Rationale: 6MM
8.2 United States
8.2.1 Prevalence of Symptomatic AATD in the United States
8.2.2 Diagnosed population of AATD in the United States
8.2.3 Genotype of AATD Diagnosed patients in the United States
8.2.4 Comorbidity associated with AATD in the United States
8.3 EU5
8.3.1 Germany
8.3.1.1 Prevalence of Symptomatic AATD in Germany
8.3.1.2 Diagnosed population of AATD in Germany
8.3.1.3 Genotype of AATD Diagnosed patients in Germany
8.3.1.4 Comorbidity associated with AATD in Germany
8.3.2 France
8.3.2.1 Prevalence of Symptomatic AATD in France
8.3.2.2 Diagnosed population of AATD in France
8.3.2.3 Genotype of AATD Diagnosed patients in France
8.3.2.4 Comorbidity associated with AATD in France
8.3.3 Italy
8.3.3.1 Prevalence of Symptomatic AATD in Italy
8.3.3.2 Diagnosed population of AATD in Italy
8.3.3.3 Genotype of AATD Diagnosed patients in Italy
8.3.3.4 Comorbidity associated with AATD in Italy
8.3.4 Spain
8.3.4.1 Prevalence of Symptomatic AATD in Spain
8.3.4.2 Diagnosed population of AATD in Spain
8.3.4.3 Genotype of AATD Diagnosed patients in Spain
8.3.4.4 Comorbidity associated with AATD in Spain
8.3.5 United Kingdom
8.3.5.1 Prevalence of Symptomatic AATD in the United Kingdom
8.3.5.2 Diagnosed population of AATD in the United Kingdom
8.3.5.3 Genotype of AATD Diagnosed patients in the United Kingdom
8.3.5.4 Comorbidity associated with AATD in the United Kingdom

9 Treatment
9.1 Current therapies
9.1.1 Augmentation Therapy
9.1.2 Gene Therapy strategies
9.1.3 Lifestyle Changes
9.1.4 Novel therapeutics

10 Treatment Algorithm
10.1 Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
10.2 Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease

11 Unmet Needs

12 Organizations contributing toward Alpha Antitrypsin Deficiency

13 Case Reports
13.1 An unusual case of alpha-1-antitrypsin deficiency: SZ/Z
13.2 The Importance of Early Identification of Alpha-1 Antitrypsin Deficiency
13.3 A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis

14 Appendix
14.1 Bibliography
14.2 Report Methodology

15 Capabilities

16 Disclaimer

17 About the Publisher
Note: Product cover images may vary from those shown
Adroll
adroll